Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset

HRS-5346 Is In Phase II In China

 
• By Mandy Jackson
  
Merck now has two oral clinical-stage lipid-lowering drug candidates (Shutterstock)

More from Deals

More from Scrip